Seeking Alpha

Idenix Pharmaceuticals (IDIX +11.4%) pops this morning after saying it's entered into a...

Idenix Pharmaceuticals (IDIX +11.4%) pops this morning after saying it's entered into a non-exclusive collaboration with Janssen Pharmaceuticals for the clinical development of antiviral Hepatitis C vaccine combination therapies. The plans include an initial drug-drug interaction study to begin in the first quarter of 2013, followed by phase II studies pending approval from regulatory authorities.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs